Spiramycin (hexanedioate)

CAS: 11034-40-5 F: C49H84N2O18 W: 989.19

Spiramycin hexanedioate (Rovamycin) is a macrolide antibiotic produced by Streptomyces ambofaciens with against bacteria

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Spiramycin hexanedioate (Rovamycin) is a macrolide antibiotic produced by Streptomyces ambofaciens with against bacteria and Toxoplasma gondii activities, and also has antiparasitic effect. Spiramycin hexanedioate is composed of a 16-member lactone ring, on which three sugars (mycaminose, forosamine, and mycarose) are attached[1][2].
Target	Bacterial
Invitro	Spiramycin (24 hours; 1-1000 μM; T. gondii infected HeLa cells and HeLa cells) treatment reduces the cytotoxicity, and shows anti-Toxoplasma gondii activity, with IC50 values of 189 μM for HeLa cells; and 262 μM for T. gondii-infected HeLa cells[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Spiramycin (hexanedioate) 相关抗体: Cell Viability Assay[3] Cell Line:
In Vivo	Spiramycin (100 mg/kg; intraperitoneal injection; every day; for 4 days; female KM mice) treatment reduces the number of tachyzoites, and reduces hepatotoxicity and significantly enhances antioxidative effects. Spiramycin treatment also decreases in the degree of granulomatous inflammation in the liver[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	11034-40-5
Formula	C49H84N2O18
Molar Mass	989.19
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Nguyen HC, et al. Post-PKS tailoring steps of the spiramycin macrolactone ring in Streptomyces ambofaciens. Antimicrob Agents Chemother. 2013 Aug;57(8):3836-42. [2]. Etewa SE, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018 Mar;42(1):102-113. [3]. Guo HY, et al. Synthesis and Biological Evaluation of (+)-Usnic Acid Derivatives as Potential Anti-Toxoplasma gondii Agents. J Agric Food Chem. 2019 Aug 28;67(34):9630-9642.